Decline in Omicron Neutralization Observed With Moderna Booster After 6 Months
The 100mcg booster dose of mRNA-1273, mRNA-1273.211 or mRNA-1273.213 generated similar neutralizing antibody levels.
Diagnosis & Disease Information
Comparison of COVID-19 Variants of Concern: Is Omicron Less Severe?
Researchers sought to assess outcomes among patients in South Africa who were hospitalized with COVID-19 infection during the Omicron wave compared with previous waves.
COVID-19 Vaccination Does Not Impact Fertility, Study Says
Participants were asked to report on COVID-19 vaccination status and prior SARS-CoV-2 infection, in addition to income and education levels, lifestyle, and reproductive and medical histories.
A New Year for COVID-19 and the Pandemic: Triumphs and Challenges
Dr Ryan Maves, CHEST COVID-19 Task Force Chair, talks about COVID-19-related triumphs of 2021, what clinicians can do now, and challenges for 2022.
COVID-19 Vaccination Linked to Small Increase in Menstrual Cycle Length
Data from the Natural Cycles app was analyzed for an association between COVID-19 vaccination menstrual cycle changes.
Efficacy, Safety of the Ad5-nCoV Vaccine for Protection Against COVID-19
Researchers conducted a study to determine the safety and efficacy of the Ad5-nCoV vaccine for protection against SARS-CoV-2 infection in adult patients.
FDA Shortens Booster Dose Interval for Moderna COVID-19 Vaccine
The Moderna booster dose is authorized for individuals 18 years of age and older.
CDC Recommends COVID-19 Vaccine Booster Dose for 12- to 15-Year-Olds
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine in individuals 12 to 15 years of age at least 5 months after completion of the primary series. The advisory panel’s recommendations follow a similar decision made by…
Moderna COVID-19 Vaccine Booster Ups Antibody Levels Against Omicron
The study was conducted at laboratories established by the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center at Duke University Medical Center.
Early Data Show Evusheld Retains Neutralizing Activity Against Omicron
The FDA study shows that the neutralizing potency of the antibody combination was within the range of neutralizing titers found in an individual previously infected with COVID-19.
- Loading...
Loading...
Loading... 
Loading...